NEW YORK (GenomeWeb News) – Medison will make available CardioDx's Corus CAD diagnostic test for obstructive coronary artery disease in Israel as part of an agreement announced today.

Under the terms of the deal, Medison will market and sell Corus CAD in Israel, where heart disease is the second-leading cause of death and responsible for 16 percent of all deaths annually, the companies said. Blood samples from patients in Israel will be shipped to CardioDx's CLIA-certified laboratory in Palo Alto, Calif., for analysis and test reporting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.